BIOCON LIMITED.
Latest filings
Next results: Wed, 4 Nov · Financial Results- Biocon Q2 FY27 results and investor call scheduled for November 4 · Results
- Biocon expands Yesintek market rights across nine more markets · Business Updates
- Biocon settles Genentech patent dispute, secures launch dates · Business Updates
Snapshot
What the business is, and whether it's a good one at a fair price.
Operates as a biopharmaceutical company with three reporting segments. Biosimilars is the largest at 60.2% of segment revenue (₹10,431.2 crore in FY26) and makes biologic copies of approved drugs — insulins, ustekinumab (sold as Yesintek), adalimumab, aflibercept (Yesafili) and denosumab — selling to global markets, with 12 biosimilar products commercialized worldwide. The CRDMO segment (21.6%, ₹3,738.7 crore) is the Syngene contract research, development and manufacturing business that serves external pharma clients. Generics (18.3%, ₹3,168.1 crore) sells small-molecule generic finished dosages and APIs, including a legacy lenalidomide contribution. Cost structure is dominated by materials at 31.2% of revenue and employees at 20.7%, with depreciation at 11.6% and capex at 10.6% of revenue, reflecting the asset-heavy biologics manufacturing base.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from BIOCON LIMITED.'s filed financials and exchange disclosures
What does BIOCON LIMITED. do?
BIOCON LIMITED. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol BIOCON.
Is BIOCON LIMITED. profitable?
Yes. Over the trailing twelve months BIOCON LIMITED. reported a net profit of ₹416 Cr on revenue of ₹17,321 Cr.
Does BIOCON LIMITED. pay a dividend?
Yes. The dividend yield is 0.16% at the current price. It paid out 25% of its profit as dividend in FY26.
Is BIOCON LIMITED. debt-free?
No. It reported borrowings of ₹14,825 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹12,408 Cr after cash. Debt stands at 0.40× equity. That is higher than 76% of its 166 Pharmaceuticals peers.
Is BIOCON LIMITED. expensive compared with its peers?
On trailing P/E, BIOCON LIMITED. ranks 141 of 158 in Pharmaceuticals — cheaper than 11% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the BIOCON LIMITED. share price move in a day?
On a typical session BIOCON LIMITED. moves 0.90% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
When are BIOCON LIMITED.'s next results?
Financial Results on Wed, 4 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track BIOCON LIMITED.'s announcements?
Every NSE and BSE filing by BIOCON LIMITED. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.